Evidence map›Paper›PMID 26181366›Full record

ArticleBioscience reports2015

Uncoupling protein 2 mediates resistance to gemcitabine-induced apoptosis in hepatocellular carcinoma cell lines.

Guangsheng Yu, Jun Liu, Kesen Xu, Jiahong Dong

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Epicatechin DecreasesInternational journal of molecular sciences · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Guangsheng YuDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital affiliated to Shandong University, Jinan 250021, China Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, China.
Jun LiuDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital affiliated to Shandong University, Jinan 250021, China.
Kesen XuDepartment of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, China jiahongdong1@163.com kesenxu@163.com.
Jiahong DongDepartment of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, China Department of Hepatobiliary Surgery, Chinese General PLA Hospital, Beijing 100853, China jiahongdong1@163.com kesenxu@163.com.
Qilu Hospital of Shandong University · CNShandong Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress induction is a common effector pathway for commonly used chemotherapeutic agents like gemcitabine (GEM) in hepatocellular carcinoma (HCC) patients. However, GEM alone or in combination with oxiplatin hardly renders any survival benefits to HCC patients. Mitochondrial uncoupling protein 2 (UCP2) is known to suppress mitochondrial reactive oxygen species (ROS) generation, thus mitigating oxidative stress-induced apoptosis. We demonstrate in the present study, using a panel of HCC cell lines that sensitivity to GEM in HCC well correlate with the endogenous level of UCP2 protein expression. Moreover, ectopic overexpression of UCP2 in a HCC cell line with low endogenous UCP2 expression, HLE, significantly decreased mitochondrial superoxide induction by the anti-cancer drug GEM. Conversely, UCP2 mRNA silencing by RNA interference in HCC cell lines with high endogenous UCP2 expression significantly enhanced GEM-induced mitochondrial superoxide generation and apoptosis. Cumulatively, our results suggest a critical role for mitochondrial uncoupling in GEM resistance in HCC cell lines. Hence, synergistic targeting of UCP2 in combination with other chemotherapeutic agents might be more potent in HCC patients.

Indexed as

ApoptosisCarcinoma, HepatocellularDeoxycytidineDrug Resistance, NeoplasmGemcitabineHep G2 CellsHumansIon ChannelsLiver NeoplasmsMitochondrial ProteinsNeoplasm ProteinsUncoupling Protein 2DeoxycytidineGemcitabineIon ChannelsMitochondrial ProteinsNeoplasm ProteinsUCP2 protein, humanUncoupling Protein 2chemoresistancegemcitabinehepatocellular carcinoma (HCC)uncoupling protein 2 (UCP2)

Identifiers

PMID26181366
PMCPMC4613703
OpenAlexW1853519360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.